Polyarteritis nodosa epidemiology and demographics
|
Polyarteritis nodosa Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polyarteritis nodosa epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Polyarteritis nodosa epidemiology and demographics |
|
Polyarteritis nodosa epidemiology and demographics in the news |
|
Risk calculators and risk factors for Polyarteritis nodosa epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]
Overview
Epidemiology and Demographics
Incidence
=
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. ===
Prevalence
=
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually. ===
Case-fatality rate/Mortality rate
=
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range]. ===
Age
=
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group]. ===
Race
=
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. ===
Gender
=
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1. ===
Region
=
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2]. ===
Developed Countries
Developing Countries
PAN is a very uncommon disease and a rare form of vasculitis. Population prevalence estimates for polyarteritis nodosa (PAN) range from 2 to 33 per million across the European Countries [1] and the annual incidence in three regions of Europe was estimated to be 4.4 to 9.7 per million [2].
PAN is commoner in men than women at a predominance rate of 1.5: 1 [3]. It occurs in all ethnic groups. Most cases of PAN occur in the 5th to 6th decade of life. It can also occur in children although this form of presentation is very rare. PAN has been associated with hepatitis B virus infection.
References
- ↑ Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M (2007). "Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden". Rheumatology (Oxford). 46 (8): 1329–37. doi:10.1093/rheumatology/kem107. PMID 17553910.
- ↑ Watts RA, Lane SE, Bentham G, Scott DG (2000). "Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom". Arthritis Rheum. 43 (2): 414–9. doi:10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0. PMID 10693883.
- ↑ Mahr A, Guillevin L, Poissonnet M, Aymé S (2004). "Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate". Arthritis Rheum. 51 (1): 92–9. doi:10.1002/art.20077. PMID 14872461.